Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence
Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure. It is, however, unclear which available alternative has the most favorable economic profile. Some available options are: trivalent (TIV) an...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis Group
2019-05-01
|
| סדרה: | Human Vaccines & Immunotherapeutics |
| נושאים: | |
| גישה מקוונת: | http://dx.doi.org/10.1080/21645515.2019.1578597 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|